Citations

Showing 10 of 108119 citations.

Effect of Shared Decision‐Making for Stroke Prevention on Treatment Adherence and Safety Outcomes in Patients With Atrial Fibrillation: A Randomized Clinical Trial
Noseworthy, Peter A. , Branda, Megan E. , Kunneman, Marleen , Hargraves, Ian , Sivly, Angela , Brito, Juan P. , Burnett, Bruce , Zeballos‐Palacios, Claudia , Suzuki, Takeki , Lee, Alexander T., Gorr, Haeshik, McCarthy, Sarah , Shah, Nilay D. , Fleming, Kirsten, Haffke, Alexander, Muegge, Jule , Poplau, Sara , Simpson, Benjamin , Vang, Miamoua, Wambua, Mike , Anderson, Joel, Behnken, Emma , Cabalka, Renee, Ferrara, Michael J. , Giblon, Rachel , Inselman, Jonathan , Olive, Marc, Organick, Paige, Spencer‐Bonilla, Gabriela , Stier, Amy, Thota, Anjali, Ting, Henry H. , Vanmeter, Derek , Nicollet, Park, Abullarade, Carol, Keune, Shelly, Smith, Timothy D. , Barksdale, Bryan, Peters, Roma, Price, Memrie, Watson, Connie, Wolfe, Douglas A. , Haynes, Brian, Daniels, Paul R. , Jaeger, Thomas M. , McCarthy, Sarah R. , Hargraves, Ian G, Sivly, Angela L, Suzuki, Takeki , Jackson, Elizabeth A , McCarthy, Sarah R , Montori, Victor M , Noseworthy, Peter A , Branda, Megan , Brito, Juan P , Burnett, Bruce, Linzer, Mark , Jackson, Elizabeth A. , Hess, Erik P. , Montori, Víctor M. , Fleming, Kirsten, Burnett, Bruce, Hamilton, James, Simpson, Benjamin, Bellolio, Fernanda , Fleming, Kirsten, LeBlanc, Annie , Lee, Alexander , Burnett, Bruce, Harvey, Lisa Anne , Stephens, Shannon W. , Hamilton, James, Hickey, Theresa, Guyatt, Gordon , Tomlinson, George , Gersh, Bernard J. , McBane, Robert D. , McCarthy, Sarah R.

Mayo Clinic

Journal of the American Heart Association | January 13, 2022 | Volume: 11 | Issue: 2 | Pages: No page available

10.1161/jaha.121.023048 | PMID 35023356 Get It

Background Guidelines promote shared decision‐making (SDM) for anticoagulation in patients with atrial fibrillation. We recently showed that adding a within‐encounter SDM tool to usual care (UC) increases patient involvement in decision‐making and clinician satisfaction, without affecting encounter length. We aimed to estimate the extent to which use of an SDM tool changed adherence to the decided care plan and clinical safety end points. Methods and Results We conducted a multicenter, encounter‐level, randomized trial assessing the efficacy of UC with versus without an SDM conversation tool for use during the clinical encounter (Anticoagulation Choice) in patients with nonvalvular atrial fibrillation considering starting or reviewing anticoagulation treatment. We conducted a chart and pharmacy review, blinded to randomization status, at 10 months after enrollment to assess primary adherence (proportion of patients who were prescribed an anticoagulant who filled their first prescription) and secondary adherence (estimated using the proportion of days for which treatment was supplied and filled for direct oral anticoagulant, and as time in therapeutic range for warfarin). We also noted any strokes, transient ischemic attacks, major bleeding, or deaths as safety end points. We enrolled 922 evaluable patient encounters (Anticoagulation Choice=463, and UC=459), of which 814 (88%) had pharmacy and clinical follow‐up. We found no differences between arms in either primary adherence (78% of patients in the SDM arm filled their first prescription versus 81% in UC arm) or secondary adherence to anticoagulation (percentage days covered of the direct oral anticoagulant was 74.1% in SDM versus 71.6% in UC; time in therapeutic range for warfarin was 66.6% in SDM versus 64.4% in UC). Safety outcomes, mostly bleeds, occurred in 13% of participants in the SDM arm and 14% in the UC arm. Conclusions In this large, randomized trial comparing UC with a tool to promote SDM against UC alone, we found no significant differences between arms in primary or secondary adherence to anticoagulation or in clinical safety outcomes. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: clinicaltrials.gov. Identifier: NCT02905032.
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)
Sideras, Kostandinos , Ginos, Brenda, Tenglin, Richard C., Liu, Heshan , Chen, Beiyun, Tan, Winston , Gross, Gerald G, Mowat, Rex B., Dueck, Amylou C. , Perez, Edith A. , Moreno‐Aspitia, Alvaro , Hillman, David W. , Giridhar, Karthik, Ginos, Brenda F, Dueck, A. C. , Sideras, Kostandinos , Giridhar, Karthik V. , Gross, Gerald G.

Mayo Clinic

The Oncologist | January 13, 2022 | Volume: 27 | Issue: 5 | Pages: 338-e368

10.1093/oncolo/oyab065 | PMID 35445723 Get It

Abstract Background Anthracycline use in metastatic breast cancer (MBC) is hindered by cumulative exposure limits and risk of cardiotoxicity. Pixantrone, a novel aza-anthracenedione with structural similarities to mitoxantrone and anthracyclines, is theorized to exhibit less cardiotoxicity, mainly due to lack of iron binding. We conducted a randomized phase II study to evaluate the efficacy and safety of 2 dosing schedules of pixantrone in patients with refractory HER2-negative MBC. Methods Intravenous pixantrone was administered at 180 mg/m2 every 3 weeks (group A) versus 85 mg/m2 on days 1, 8, and 15 of a 28-day cycle (group B). Primary endpoint was objective response rate (ORR) and secondary endpoints included progression-free survival (PFS), median 6-month PFS, overall survival (OS), safety, quality of life, and serial assessment of circulating tumor cells. A 20% ORR was targeted as sufficient for further testing of pixantrone in this patient population. Results Forty-five patients were evaluable, with 2 confirmed partial responses in group A and 1 in group B. The trial was terminated due to insufficient activity. Overall median PFS and OS were 2.8 (95% confidence interval [CI]: 2.0-4.1) and 16.8 (95% CI: 8.9-21.6) months, respectively. Notable overall grade 3-4 adverse events were the following: neutrophil count decrease (62%), fatigue (16%), and decrease in ejection fraction (EF) (4%). Conclusion Pixantrone has insufficient activity in the second- and third-line MBC setting. It appears, however, to have limited cardiotoxicity. (ClinicalTrials.gov ID: NCT01086605).
Accounting for EGFR Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data
Schmid, Sabine , Jiang, Mei , Brown, M. Catherine , Fares, Aline Fusco , García-Pardo, Miguel , Soriano, Joelle , Dong, Mei , Thomas, Sera , Kohno, Takashi , Leal, Letícia Ferro , Diao, Nancy , Xie, Juntao , Wang, Zhichao , Заридзе, Давид , Świątkowska, Beata , Savić, Milan , Wenzlaff, Angela S. , Harris, Curtis C. , Caporaso, Neil E. , Ma, Hongxia , Fernández‐Tardón, Guillermo , Barnett, Matthew J, Goodman, Gary E. , Davies, Michael P.A. , Pérez‐Ríos, Mónica , Taylor, Fiona, Schoettker, Ben, Brenner, Hermann , Andrew, Angeline S. , Cox, Angela , Field, John K. , Wang, Ying , Chen, Chu , Tardón, Adonina , Shete, Sanjay , Shen, Hongbing , Landi, Maria Teresa , Schwartz, Ann G. , Qi, Lihong , Brennan, Paul , Reis, Rui Manuel , Liu, Geoffrey , Świątkowska, Beata , Mates, Dana , Wenzlaff, Angela S , Fernandez-Tardon, Guillermo , Barnett, Matthew J , Davies, Michael P A , Duell, Eric J , Brenner, Hermann , Cox, Angela , Ruano-Ravina, Alberto , Field, John K , Tardón, Adonina , Schabath, Matthew B , Schwartz, Ann G , Sakoda, Lori C , Brennan, Paul , Yang, Ping , Christiani, David C. , Reis, Rui Manuel , Hung, Rayjean J , Liu, Geoffrey , Shen, Hongbing , Dong, Mei , Holcátová, Ivana , Lissowska, Jolanta , Mateș, Dana , Duell, Eric J. , Marchand, Loı̈c Le , Schabath, Matthew B. , Ryan, Bríd M. , Sakoda, Lori C. , Yang, Ping , Zhang, Jie , Shiraishi, Kouya , Hung, Rayjean J. , Xu, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 13, 2022 | Volume: 31 | Issue: 3 | Pages: 679-687

10.1158/1055-9965.epi-21-0747 | PMID 35027437 Get It

Abstract Background: Somatic EGFR mutations define a subset of non–small cell lung cancers (NSCLC) that have clinical impact on NSCLC risk and outcome. However, EGFR-mutation-status is often missing in epidemiologic datasets. We developed and tested pragmatic approaches to account for EGFR-mutation-status based on variables commonly included in epidemiologic datasets and evaluated the clinical utility of these approaches. Methods: Through analysis of the International Lung Cancer Consortium (ILCCO) epidemiologic datasets, we developed a regression model for EGFR-status; we then applied a clinical-restriction approach using the optimal cut-point, and a second epidemiologic, multiple imputation approach to ILCCO survival analyses that did and did not account for EGFR-status. Results: Of 35,356 ILCCO patients with NSCLC, EGFR-mutation-status was available in 4,231 patients. A model regressing known EGFR-mutation-status on clinical and demographic variables achieved a concordance index of 0.75 (95% CI, 0.74–0.77) in the training and 0.77 (95% CI, 0.74–0.79) in the testing dataset. At an optimal cut-point of probability-score = 0.335, sensitivity = 69% and specificity = 72.5% for determining EGFR-wildtype status. In both restriction-based and imputation-based regression analyses of the individual roles of BMI on overall survival of patients with NSCLC, similar results were observed between overall and EGFR-mutation-negative cohort analyses of patients of all ancestries. However, our approach identified some differences: EGFR-mutated Asian patients did not incur a survival benefit from being obese, as observed in EGFR-wildtype Asian patients. Conclusions: We introduce a pragmatic method to evaluate the potential impact of EGFR-status on epidemiological analyses of NSCLC. Impact: The proposed method is generalizable in the common occurrence in which EGFR-status data are missing.
Intertrochanteric hip stress fracture in a male ultramarathon runner
Nadwodny, Jeffrey , Pujalte, George , Bertasi, Tais G.O. , Huff, Tamara, Nadwodny, Jeffrey P, Bertasi, Tais Garcia de Oliveira , Pujalte, George G A

Mayo Clinic

BMJ Case Reports | January 13, 2022 | Volume: 15 | Issue: 1 | Pages: e239594

10.1136/bcr-2020-239594 | PMID 35027376 Get It

Stress fractures are injuries frequently seen in high-performance athletes, especially runners. In the femur, the most commonly affected locations are the femoral neck, condylar area and proximal shaft. Intertrochanteric fractures are much more common in the elderly population, especially among those with osteoporosis, but they can also be a result of high-energy repetitive mechanisms. We present a case of an intertrochanteric stress fracture in a young male runner. The diagnosis was suspected after persistent pain following his first marathon, and it was confirmed with an MRI. Operative fixation of the fracture was performed 22 days after the pain started, which allowed the patient to return to his activities, including 50 km marathon 4 months following the surgery.
The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms
Kelemen, Katalin

Mayo Clinic

Life | January 13, 2022 | Volume: 12 | Issue: 1 | Pages: 109

10.3390/life12010109 | PMID 35054502 Get It

Nucleophosmin (NPM1) is a multifunctional protein with both proliferative and growth-suppressive roles in the cell. In humans, NPM1 is involved in tumorigenesis via chromosomal translocations, deletions, or mutation. Acute myeloid leukemia (AML) with mutated NPM1, a distinct diagnostic entity by the current WHO Classification of myeloid neoplasm, represents the most common diagnostic subtype in AML and is associated with a favorable prognosis. The persistence of NPM1 mutation in AML at relapse makes this mutation an ideal target for minimal measurable disease (MRD) detection. The clinical implication of this is far-reaching because NPM1-mutated AML is currently classified as being of standard risk, with the best treatment strategy (transplantation versus chemotherapy) yet undefined. Myeloid neoplasms with NPM1 mutations and <20% blasts are characterized by an aggressive clinical course and a rapid progression to AML. The pathological classification of these cases remains controversial. Future studies will determine whether NPM1 gene mutation may be sufficient for diagnosing NPM1-mutated AML independent of the blast count. This review aims to summarize the role of NPM1 in normal cells and in human cancer and discusses its current role in clinical management of AML and related myeloid neoplasms.
Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach
Cho, May T., Gholami, Sepideh , Gui, Dorina , Tejaswi, Sooraj , Abi‐Jaoudeh, Nadine , Jutric, Zeljka , Samarasena, Jason , Li, Xiaodong , Valerin, Jennifer Brooke, Mercer, Jacob , Dayyani, Farshid , Achilonu, Conrad Chibunna , Fananapazir, Ghaneh , Mercer, Jacob , Dayyani, Farshid , Abi-Jaoudeh, Nadine , Achilonu, Conrad C , Cho, May

Mayo Clinic

Cancers | January 13, 2022 | Volume: 14 | Issue: 2 | Pages: 392

10.3390/cancers14020392 | PMID 35053557 Get It

Cholangiocarcinoma (CCA) is a heterogenous group of malignancies originating in the biliary tree, and associated with poor prognosis. Until recently, treatment options have been limited to surgical resection, liver-directed therapies, and chemotherapy. Identification of actionable genomic alterations with biomarker testing has revolutionized the treatment paradigm for these patients. However, several challenges exist to the seamless adoption of precision medicine in patients with CCA, relating to a lack of awareness of the importance of biomarker testing, hurdles in tissue acquisition, and ineffective collaboration among the multidisciplinary team (MDT). To identify gaps in standard practices and define best practices, multidisciplinary hepatobiliary teams from the University of California (UC) Davis and UC Irvine were convened; discussions of the meeting, including optimal approaches to tissue acquisition for diagnosis and biomarker testing, communication among academic and community healthcare teams, and physician education regarding biomarker testing, are summarized in this review.
Silk Embolic Material for Catheter‐Directed Endovascular Drug Delivery (Adv. Mater. 2/2022)
Albadawi, Hassan , Gündüz, Şeyda , Rehman, Suliman, d’Amone, Luciana , Mayer, Joseph L. , Omenetto, Fiorenzo G. , Hu, Jingjie , Zhang, Zefu , Salomao, Marcela , Öklü, Rahmi

Mayo Clinic

Advanced Materials | January 13, 2022 | Volume: 34 | Issue: 2 | Pages: No page available

10.1002/adma.202270017 Get It

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol
Zheng, Weili , Chilazi, Michael , Park, Jihwan, Sathiyakumar, Vasanth, Donato, Leslie J. , Meeusen, Jeffrey W. , Lazo, Mariana, Güallar, Eliseo , Kulkarni, Krishnaji R., Jaffe, Allan S. , Santos, Raúl D. , Tóth, Peter P. , Jones, Steven R., Martin, Seth S. , Lazo, Mariana , Santos, Raul D , Guallar, Eliseo , Martin, Seth S , Lazo, Mariana , Donato, Leslie , Zheng, Weili , Chilazi, Michael , Park, Jihwan, Sathiyakumar, Vasanth, Meeusen, Jeffrey W. , Kulkarni, Krishnaji R., Jaffe, Allan S. , Toth, Peter P. , Jones, Steven R.

Mayo Clinic

Journal of the American Heart Association | January 13, 2022 | Volume: 11 | Issue: 2 | Pages: No page available

10.1161/jaha.121.023136 | PMID 35023348 Get It

Background Accurate measurement of the cholesterol within lipoprotein(a) (Lp[a]‐C) and its contribution to low‐density lipoprotein cholesterol (LDL‐C) has important implications for risk assessment, diagnosis, and treatment of atherosclerotic cardiovascular disease, as well as in familial hypercholesterolemia. A method for estimating Lp(a)‐C from particle number using fixed conversion factors has been proposed (Lp[a]‐C from particle number divided by 2.4 for Lp(a) mass, multiplied by 30% for Lp[a]‐C). The accuracy of this method, which theoretically can isolate “Lp(a)‐free LDL‐C,” has not been validated. Methods and Results In 177 875 patients from the VLDbL (Very Large Database of Lipids), we compared estimated Lp(a)‐C and Lp(a)‐free LDL‐C with measured values and quantified absolute and percent error. We compared findings with an analogous data set from the Mayo Clinic Laboratory. Error in estimated Lp(a)‐C and Lp(a)‐free LDL‐C increased with higher Lp(a)‐C values. Median error for estimated Lp(a)‐C <10 mg/dL was −1.9 mg/dL (interquartile range, −4.0 to 0.2); this error increased linearly, overestimating by +30.8 mg/dL (interquartile range, 26.1–36.5) for estimated Lp(a)‐C ≥50 mg/dL. This error relationship persisted after stratification by overall high‐density lipoprotein cholesterol and high‐density lipoprotein cholesterol subtypes. Similar findings were observed in the Mayo cohort. Absolute error for Lp(a)‐free LDL‐C was +2.4 (interquartile range, −0.6 to 5.3) for Lp(a)‐C<10 mg/dL and −31.8 (interquartile range, −37.8 to −26.5) mg/dL for Lp(a)‐C≥50 mg/dL. Conclusions Lp(a)‐C estimations using fixed conversion factors overestimated Lp(a)‐C and subsequently underestimated Lp(a)‐free LDL‐C, especially at clinically relevant Lp(a) values. Application of inaccurate Lp(a)‐C estimations to correct LDL‐C may lead to undertreatment of high‐risk patients.
Community-Engaged Bidirectional Crisis and Emergency Risk Communication With Immigrant and Refugee Populations During the COVID-19 Pandemic
Asiedu, Gladys B. , Njeru, Jane W. , Weis, Jennifer A., Lantz, Kiley, Abbenyi, Adeline, Molina, Luz, Ahmed, Yahye, Goodson, Miriam, Torres-Herbeck, Gloria, Nur, Omar, Capetillo, Graciela Porraz, Mohamed, Ahmed A. , Sia, Irene G. , Wieland, Mark L , Porraz Capetillo, Graciela, Sia, Irene G , Wieland, Mark L. , Osman, Ahmed

Mayo Clinic

Public Health Reports® | January 13, 2022 | Volume: 137 | Issue: 2 | Pages: 352-361

10.1177/00333549211065514 | PMID 35023414 Get It

Objectives: This study was conducted to assess an intervention that was created by a community–academic partnership to address COVID-19 health inequities. We evaluated a community-engaged bidirectional pandemic crisis and emergency risk communication (CERC) framework with immigrant and refugee populations during the COVID-19 pandemic. Methods: A 17-year community-engaged research partnership adopted a CERC framework in March 2020 to address COVID-19 prevention, testing, and socioeconomic impacts with immigrant and refugee groups in southeast Minnesota. The partnership used bidirectional communication between communication leaders and their social networks to refine messages, leverage resources, and advise policy makers. We conducted a mixed-methods evaluation for intervention acceptability, feasibility, reach, adaptation, and sustainability through multisource data, including email communications, work group notes, semistructured interviews, and focus groups. Results: The intervention reached at least 39 000 people in 9 months. It was implemented as intended and perceived efficacy was high. Frequent communication between community and academic partners allowed the team to respond rapidly to concerns and facilitated connection of community members to resources. Framework implementation also led to systems and policy changes to meet the needs of immigrant and refugee populations. Conclusions: Community-engaged CERC is feasible and sustainable and can reduce COVID-19 disparities through shared creation and dissemination of public health messages, enhanced connection to existing resources, and incorporation of community perspectives in regional pandemic mitigation policies.